...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Still waiting for that BETonMACE CKD sub-study 7 months later

Barsax,

" believe we will have an opportunity for an early trial halt due to overwhelming efficacy."

Exactly.  The key is to hone in on the patient group in which apabetalone works well, because it works really, really well in them.  And RVX knows which patient group that is now.  Also, use of biomarker endpoints could really speed things up - less waiting for non-existent MACE to happen.

Jupe

Share
New Message
Please login to post a reply